Dahlman Rose Starts CVS Caremark (CVS) at Buy, Strong Business Model
Tweet
Share
E-mailGet Alerts CVS Hot Sheet
Price: $97.16 +2.28%
Rating Summary:
34 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
34 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Dahlman Rose initiates coverage on shares of CVS Caremark (NYSE: CVS) with a Buy rating and $40 price target. The stock is currently trading at a 15 percent discount to its peers.
The firm likes CVS's combined retail/PBM drug distribution model, but states that the company has made it hard to like given a number of execution missteps. Profitability should begin to show some signs of improvement as the 2012 selling season has started off strong.
CVS' front end business continues to show solid growth following a surprisingly robust performance through the recession, this was helped by acquisitions. The firm reports that its Extra Care loyalty card is industry-leading, and the information that it gathers from customers behaviors should help it maintain a relevant offering.
For more ratings news on CVS Caremark click here and for the rating history of CVS Caremark click here.
Shares of CVS Caremark closed at $37.44 yesterday.
The firm likes CVS's combined retail/PBM drug distribution model, but states that the company has made it hard to like given a number of execution missteps. Profitability should begin to show some signs of improvement as the 2012 selling season has started off strong.
CVS' front end business continues to show solid growth following a surprisingly robust performance through the recession, this was helped by acquisitions. The firm reports that its Extra Care loyalty card is industry-leading, and the information that it gathers from customers behaviors should help it maintain a relevant offering.
For more ratings news on CVS Caremark click here and for the rating history of CVS Caremark click here.
Shares of CVS Caremark closed at $37.44 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CVS Health (CVS) PT Raised to $118 at JPMorgan
- RBC Capital Starts Krystal Biotech (KRYS) at Outperform
- CVS Health Enhances Its Direct-to-Consumer Weight Management Offerings To Improve Access, Affordability, Care and Support for GLP-1 Medications
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
